Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Amgen Completes $200 Million Biologics Facility in Singapore

publication date: Nov 20, 2014
Amgen has finished building its new $200 million next-generation biomanufacturing facility in Singapore, ushering in a new era for the company. The plant features a continuous manufacturing model that replaces biotech's traditional batch processing. Robert Bradway, Amgen's Chairman and CEO, earlier claimed the technology cuts costs dramatically: capital costs by 75%, operating expenses by 67% and manufacturing time by 50% -- overall, continuous manufacturing reduces the cost per gram of protein by 60%, he said. More details....

Stock Symbol: (NSDQ: AMGN)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital